Pharma Focus Europe
July 24, 2024
ViroCell Biologics, a contract development and manufacturing organization specializing in GMP viral vector production, has secured a five-year Master Services Agreement (MSA) with a major U.S. NCI-designated cancer center. This partnership allows the cancer center to utilize ViroCell’s extensive range of services for pre-clinical and clinical viral vector needs, accelerating the development of novel gene-modified cell therapies.
Under the MSA, ViroCell will provide services including viral vector design, MicroBatch© production, pre-clinical batch manufacturing, and process development. Additionally, clinical services will encompass global plasmid sourcing, GMP manufacturing, expedited quality control release testing, regulatory support, and in-house Qualified Person (QP) batch review for global clinical trials.
This agreement follows ViroCell’s successful GMP production of a lentivirus vector for the cancer center’s clinical trials involving a new engineered T cell receptor (TCR) therapy. The vector was delivered for clinical use within five months of initiating GMP manufacture.
“We are excited to formalize this Master Services Agreement with one of the leading cancer research centers. This partnership underscores our commitment to providing specialized GMP viral vector manufacturing services to pioneering research organizations, both in academia and industry. We are eager to support their innovative cancer treatment development efforts.”